Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Chronically Increased Amino Acids Improve Insulin Secretion, Pancreatic Vascularity, and Islet Size in Growth-Restricted Fetal Sheep.

Endocrinology | 2016

Placental insufficiency is associated with reduced supply of amino acids to the fetus and leads to intrauterine growth restriction (IUGR). IUGR fetuses are characterized by lower glucose-stimulated insulin secretion, smaller pancreatic islets with less β-cells, and impaired pancreatic vascularity. To test whether supplemental amino acids infused into the IUGR fetus could improve these complications of IUGR we used acute (hours) and chronic (11 d) direct fetal amino acid infusions into a sheep model of placental insufficiency and IUGR near the end of gestation. IUGR fetuses had attenuated acute amino acid-stimulated insulin secretion compared with control fetuses. These results were confirmed in isolated IUGR pancreatic islets. After the chronic fetal amino acid infusion, fetal glucose-stimulated insulin secretion and islet size were restored to control values. These changes were associated with normalization of fetal pancreatic vascularity and higher fetal pancreatic vascular endothelial growth factor A protein concentrations. These results demonstrate that decreased fetal amino acid supply contributes to the pathogenesis of pancreatic islet defects in IUGR. Moreover, the results show that pancreatic islets in IUGR fetuses retain their ability to respond to increased amino acids near the end of gestation after chronic fetal growth restriction.

Pubmed ID: 27501184 RIS Download

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK088139
  • Agency: NIDDK NIH HHS, United States
    Id: R03 DK102972
  • Agency: NCATS NIH HHS, United States
    Id: KL2 TR001080
  • Agency: NCATS NIH HHS, United States
    Id: TL1 TR001081
  • Agency: NIDDK NIH HHS, United States
    Id: K01 DK090199
  • Agency: NICHD NIH HHS, United States
    Id: K12 HD057022
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR001082
  • Agency: NICHD NIH HHS, United States
    Id: K08 HD060688
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD079404
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK084842
  • Agency: NICHD NIH HHS, United States
    Id: K12 HD068372

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Insulin (antibody)

RRID:AB_10013624

This polyclonal targets Porcine pancreatic insulin

View all literature mentions

GLK antibody (antibody)

RRID:AB_10673863

This polyclonal targets GLK antibody

View all literature mentions

VEGF (147) (antibody)

RRID:AB_2212666

This polyclonal targets VEGF (147)

View all literature mentions

Anti-Caspase 8 (antibody)

RRID:AB_310250

This polyclonal targets Caspase 8

View all literature mentions